Showing results (251-260 of 335) with videos related to
Sort By:
Pageof 34
Seminars in Oncology|October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working GroupJames H Doroshow, Timothy W Synold, David Gandara, et al.Future Oncology (London, England)|February 21, 2018
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinomaThomas T DeLeon, Daniel H Ahn, James M Bogenberger, et al.Journal of Liposome Research|July 15, 2010
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsWilliam C Zamboni, Lauren J Maruca, Sandra Strychor, et al.Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.Oncotarget|August 29, 2015
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancerMichael T Barrett, Karen S Anderson, Elizabeth Lenkiewicz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.Cancer|June 15, 2007
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancerAmanda C Ashley, Daniel J Sargent, Steven R Alberts, et al.Clinical Colorectal Cancer|August 5, 2011
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancerBenedito A Carneiro, Ramesh K Ramanathan, Marwan G Fakih, et al.Pageof 34